Biorepository for studying kidney disease in individuals with ApoL1 mutations
Duke APOL1 Research Biorepository
This study is trying to understand how certain genetic changes in the ApoL1 gene affect kidney disease in people of African ancestry by collecting samples from those with and without kidney problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Duke University Academic / other |
| Locations | 1 site (Durham, North Carolina) |
| Trial ID | NCT04160507 on ClinicalTrials.gov |
What this trial studies
The Duke ApoL1 Nephropathy Biorepository focuses on understanding end stage kidney disease (ESKD) by collecting samples from individuals with and without kidney disease, particularly those of African ancestry. This observational study aims to explore the genetic factors, specifically mutations in the ApoL1 gene, that contribute to the higher prevalence of kidney failure in this population. By utilizing advanced techniques to create kidney-like cells from induced pluripotent stem cells (iPSCs), researchers hope to uncover the mechanisms linking these mutations to kidney disease. The study will include both affected individuals and healthy controls to provide a comprehensive understanding of the condition.
Who should consider this trial
Good fit: Ideal candidates include self-identified African Americans, Afro-Caribbean individuals, and other black individuals with varying stages of kidney disease or healthy black adults aged 50 and older with no known history of kidney disease.
Not a fit: Patients with diabetic nephropathy or healthy controls with any form of kidney disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for end stage kidney disease in populations affected by ApoL1 mutations.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in understanding genetic contributions to kidney disease, particularly in populations with specific genetic backgrounds.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Majority of subjects recruited for this study will be self-identified African Americans, Afro-Caribbean and other black individuals. Study subjects will include individuals at various stages of kidney disease and those without any clinical evidence of kidney disease. * Healthy black adults, age 50 and older with no known history of kidney disease will be recruited as controls Exclusion Criteria: * Black adult cases with diabetic nephropathy * Healthy controls with kidney disease
Where this trial is running
Durham, North Carolina
- Duke University Medical Center — Durham, North Carolina, United States (Recruiting)
Study contacts
- Study coordinator: Opeyemi Olabisi, MD/PHD
- Email: opeyemi.olabisi@duke.edu
- Phone: 919-660-6987
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.